ArticleFrontiers in pharmacology2025
Clinical-oriented tacrolimus dosing algorithms in kidney transplant based on genetic algorithm and deep forest.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Artificial Intelligence and Predictive Modelling for Precision Dosing of Immunosuppressants in Kidney Transplantation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Towards Personalized Tacrolimus Dosing Using an Algorithm-Driven Prediction Pipeline for Kidney Transplant.Drug design, development and therapy · 2026Article
- Integrating pharmacogenetic and clinical factors to predict the C0/D/W-based tacrolimus phenotype in kidney transplantation.Frontiers in pharmacology · 2026Article
- Protocol-constrained AI enhances tacrolimus dosing accuracy in kidney transplant care.Frontiers in artificial intelligence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The immunosuppressant tacrolimus (TAC) plays a crucial role in preventing rejection reactions after organ transplant. Due to a narrow therapeutic window, it is one of the long-term challenges in postoperative care, increasingly requiring a precise management due to individual variability. To alleviate the burden on clinicians and achieve an automatic and precise drug dosing, the AI-assisted personalized dosing of TAC is a promising predictive method. Methods: This study presents a clinical-oriented TAC dosing algorithm that integrates genetic algorithm (GA) with deep forest (DF) to predict both initial and follow-up doses for kidney transplant recipients. The optimized candidate variables were first conducted from numerous clinical factors by GA using support vector regression based on radial basis function. Then a smaller number of key clinical variables were confirmed for clinical relevance and ease of use by an exhaustive feature selection method. Results: Validated in a cohort of 288 recipients, the DF model combined with a few clinical variables ultimately achieved an average accuracy of 84.5% and 91.7% in the initial and follow-up dosage prediction. Conclusion: The proposed approach can provide a potential reference to algorithm-based automatic pipeline methods for drug dosing prediction and analysis in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.